Oxybutynin Chloride

DRUG4 trials

Sponsors

Alza Corporation, DE, USA, Ortho-McNeil Janssen Scientific Affairs, LLC, Academic and Community Cancer Research United, Alliance for Clinical Trials in Oncology

Conditions

Breast CarcinomaDuctal Breast Carcinoma In SituHot FlashesLobular Breast Carcinoma In SituMenopauseNo Evidence of DiseaseProstate CarcinomaUrinary Incontinence

Phase 2

The Effect of Extended-Release Oxybutynin Chloride on Vasomotor Symptoms in Healthy Post-Menopausal Women

CompletedNCT00990886

Ortho-McNeil Janssen Scientific Affairs, LLCHot Flashes, Menopause

Start: 2004-04-30End: 2005-01-31Updated: 2012-12-12

Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

CompletedNCT04600336

Alliance for Clinical Trials in OncologyProstate Carcinoma

Start: 2021-10-28End: 2024-03-11Updated: 2025-03-30

Phase 3

Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder

CompletedNCT00293839

Alza Corporation, DE, USAUrinary Incontinence

End: 2002-12-31Updated: 2025-02-03

Oxybutynin Chloride in Managing Hot Flashes

CompletedNCT02961790

Academic and Community Cancer Research UnitedBreast Carcinoma, Ductal Breast Carcinoma In Situ, Hot Flashes +2

Start: 2016-12-09End: 2018-04-27Updated: 2020-01-18

Related Papers

Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.

Journal of Clinical Oncology2024-06-053 citations

Oxybutynin Reduces Hot Flash Frequency & Severity in Breast Cancer Survivors

Oncology Times2019-01-31